HK1022330A1 - Osteoprotegerin binding proteins and receptors - Google Patents

Osteoprotegerin binding proteins and receptors

Info

Publication number
HK1022330A1
HK1022330A1 HK00101154A HK00101154A HK1022330A1 HK 1022330 A1 HK1022330 A1 HK 1022330A1 HK 00101154 A HK00101154 A HK 00101154A HK 00101154 A HK00101154 A HK 00101154A HK 1022330 A1 HK1022330 A1 HK 1022330A1
Authority
HK
Hong Kong
Prior art keywords
fragments
encoding
sequence
nucleic acid
receptors
Prior art date
Application number
HK00101154A
Other languages
English (en)
Inventor
William J Boyle
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27368158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1022330(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/842,842 external-priority patent/US5843678A/en
Priority claimed from US09/052,521 external-priority patent/US6316408B1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1022330A1 publication Critical patent/HK1022330A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK00101154A 1997-04-16 2000-02-25 Osteoprotegerin binding proteins and receptors HK1022330A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/842,842 US5843678A (en) 1997-04-16 1997-04-16 Osteoprotegerin binding proteins
US88085597A 1997-06-23 1997-06-23
US09/052,521 US6316408B1 (en) 1997-04-16 1998-03-30 Methods of use for osetoprotegerin binding protein receptors
PCT/US1998/007584 WO1998046751A1 (en) 1997-04-16 1998-04-15 Osteoprotegerin binding proteins and receptors

Publications (1)

Publication Number Publication Date
HK1022330A1 true HK1022330A1 (en) 2000-08-04

Family

ID=27368158

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00101154A HK1022330A1 (en) 1997-04-16 2000-02-25 Osteoprotegerin binding proteins and receptors

Country Status (28)

Country Link
US (1) US7923008B2 (zh)
EP (2) EP0975754B2 (zh)
JP (2) JP2001526532A (zh)
CN (1) CN1264427A (zh)
AT (1) ATE363533T1 (zh)
AU (4) AU743257B2 (zh)
BG (1) BG65242B1 (zh)
BR (1) BR9808545A (zh)
CA (1) CA2285746C (zh)
CZ (1) CZ302262B6 (zh)
DE (1) DE69837845T3 (zh)
DK (1) DK0975754T4 (zh)
EA (1) EA003636B1 (zh)
EE (1) EE05496B1 (zh)
ES (1) ES2284203T5 (zh)
HK (1) HK1022330A1 (zh)
HU (1) HU230547B1 (zh)
ID (1) ID23855A (zh)
IL (1) IL132304A0 (zh)
NO (1) NO325175B1 (zh)
NZ (1) NZ500253A (zh)
PL (1) PL190092B1 (zh)
RO (1) RO128635A2 (zh)
SI (1) SI0975754T2 (zh)
SK (1) SK288559B6 (zh)
TR (1) TR199902512T2 (zh)
TW (1) TW589376B (zh)
WO (1) WO1998046751A1 (zh)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE69738811D1 (de) 1996-12-13 2008-08-14 Schering Corp Oberflächenantigene aus Säugern
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
NZ332995A (en) 1997-04-15 2000-07-28 Snow Brand Milk Products Co Ltd A protein which binds to osteoclastogenesis inhibitory factor (OCIF)
AU2008200700C1 (en) * 1997-04-15 2013-04-04 Daiichi Sankyo Co., Ltd Novel Protein and Process for Producing The Same
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU762574B2 (en) * 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
CN1318105A (zh) * 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
DK1114166T3 (da) * 1998-09-15 2005-08-01 Pharmexa As Fremgangsmåde til nedregulering af osteoprotegerinligandaktivitet
HU228582B1 (en) 1998-10-23 2013-04-29 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
EP2339003A3 (en) 1999-06-28 2011-10-19 Genentech, Inc. Apo-2 ligand substitutional variants
BR0013391A (pt) 1999-08-17 2002-07-09 Biogen Inc Uso do receptor baff (bcma) como um agente imunoregulador
WO2001023559A1 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
DE60028830T2 (de) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
DE60134459D1 (de) * 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
IL153948A0 (en) 2000-07-27 2003-07-31 Genentech Inc Apo-2l receptor agonist and cpt-11 synergism
WO2002016551A2 (en) * 2000-08-18 2002-02-28 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
DE01973455T1 (de) 2000-09-22 2004-04-22 Immunex Corp., Seattle Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
US7488710B2 (en) 2001-01-10 2009-02-10 The United States Of America As Represented By The Department Of Health And Human Services SFRP and peptide motifs that interact with SFRP and methods of their use
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
YU103003A (sh) * 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
CA2451680C (en) 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
WO2003042344A2 (en) 2001-11-13 2003-05-22 Genentech, Inc. Apo2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
AU2011265413B2 (en) * 2002-04-05 2014-04-10 Amgen Inc. Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors
MXPA04009681A (es) * 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
EP2500032A1 (en) 2002-06-24 2012-09-19 Genentech, Inc. APO-2 ligand/trail variants and uses thereof
AU2003297833A1 (en) 2002-12-10 2004-06-30 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
RU2431676C2 (ru) 2004-08-06 2011-10-20 Дженентек, Инк. Анализы и способы с применением биомаркеров
EP2292794A3 (en) 2004-08-06 2011-07-06 Genentech, Inc. Death receptor (DR) antibody for pharmaceutical use and assays employing biomarkers for predicting sensitivity of cells to said antibody
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1915626B1 (en) 2005-08-16 2011-11-09 Genentech, Inc. Apoptosis sensitivity to apo2l/trail by testing for galnac-t14 expression in cells/tissues
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
CA2673560C (en) * 2006-12-22 2017-08-22 The Regents Of The University Of California New fusion molecule based on novel taa variant
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CA2690685A1 (en) * 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
CN101855350B (zh) * 2008-05-02 2014-12-31 国立大学法人京都大学 核重编程序方法
EP2376120A2 (en) 2008-11-25 2011-10-19 Biogen Idec MA Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
US9045403B2 (en) 2012-02-29 2015-06-02 Coyote Pharmaceuticals, Inc. Geranyl geranyl acetone (GGA) derivatives and compositions thereof
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US11427627B2 (en) 2013-09-05 2022-08-30 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
MA47775A (fr) 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
EP3713581A1 (en) 2017-11-22 2020-09-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf
IL313983A (en) 2018-03-26 2024-08-01 Amgen Inc Fully fucose-free glycoforms of antibodies are produced in cell culture
CA3152547A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
CN113621060B (zh) * 2020-05-07 2023-07-04 浙江瑞硕生物技术有限公司 一种opg抗体对及其应用
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4229080A1 (en) 2020-10-15 2023-08-23 Amgen Inc. Relative unpaired glycans in antibody production methods
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
CA3233279A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4710457A (en) 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
JP3356775B2 (ja) 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
PT639079E (pt) 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
DE69427588T2 (de) 1993-09-14 2002-04-25 Merck & Co., Inc. HUMANE PROTEIN-TYROSINPHOSPHATASE DECODIERENDE cDNA
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5641747A (en) 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
DE69434988T2 (de) * 1994-11-07 2008-03-06 Human Genome Sciences, Inc. Tumornekrose-faktor-gamma
EP0727211A1 (en) 1995-02-10 1996-08-21 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
WO1997000318A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
EP0835305B1 (en) * 1995-06-29 2005-11-23 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6046048A (en) 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US5981220A (en) 1996-03-27 1999-11-09 Human Genome Sciences, Inc. Epidermal differentiation factor
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
DE69738811D1 (de) 1996-12-13 2008-08-14 Schering Corp Oberflächenantigene aus Säugern
AU5901598A (en) 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
FR2757507B1 (fr) 1996-12-20 1999-01-29 Inst Francais Du Petrole Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
NZ332995A (en) 1997-04-15 2000-07-28 Snow Brand Milk Products Co Ltd A protein which binds to osteoclastogenesis inhibitory factor (OCIF)
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
AU7469998A (en) 1997-05-01 1998-11-24 Amgen, Inc. Chimeric opg polypeptides
WO1998054201A1 (en) 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
CN1318105A (zh) 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
KR20010085996A (ko) 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
DE60134459D1 (de) 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002016551A2 (en) 2000-08-18 2002-02-28 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
DE01973455T1 (de) 2000-09-22 2004-04-22 Immunex Corp., Seattle Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
ES2212930T1 (es) 2001-05-17 2004-08-16 Immunex Corporation Uso terapeutico de antagonistas de rank.
JP2005515159A (ja) 2001-06-06 2005-05-26 イミュネックス・コーポレーション 癌を治療するためのｒａｎｋアンタゴニストの使用
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
US6753755B2 (en) * 2001-06-28 2004-06-22 Safer Home, Inc. Electrical safety connector fuse
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6592001B2 (en) * 2001-12-18 2003-07-15 Kimberly-Clark Worldwide Dispenser for sheet material containing a dispensing port incrementally variable within a range
MXPA04009681A (es) 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
US7706431B2 (en) * 2005-06-30 2010-04-27 Nokia Corporation System and method for providing optimized receiver architectures for combined pilot and data signal tracking

Also Published As

Publication number Publication date
JP2008054682A (ja) 2008-03-13
US7923008B2 (en) 2011-04-12
EE05496B1 (et) 2011-12-15
EP0975754B1 (en) 2007-05-30
ES2284203T5 (es) 2016-03-11
DE69837845D1 (de) 2007-07-12
WO1998046751A1 (en) 1998-10-22
EA003636B1 (ru) 2003-08-28
NO995044D0 (no) 1999-10-15
NO325175B1 (no) 2008-02-11
HUP0001400A2 (en) 2000-07-28
SI0975754T2 (sl) 2016-04-29
HUP0001400A3 (en) 2001-12-28
EP1717315A3 (en) 2007-06-20
TW589376B (en) 2004-06-01
PL336311A1 (en) 2000-06-19
EP1717315A2 (en) 2006-11-02
AU2005201799B2 (en) 2008-06-12
AU743257B2 (en) 2002-01-24
PL190092B1 (pl) 2005-10-31
CN1264427A (zh) 2000-08-23
ID23855A (id) 2000-05-25
AU7120598A (en) 1998-11-11
CZ359899A3 (cs) 2000-02-16
DE69837845T3 (de) 2016-06-23
CA2285746A1 (en) 1998-10-22
BG103824A (en) 2000-05-31
AU779461B2 (en) 2005-01-27
JP2001526532A (ja) 2001-12-18
ES2284203T3 (es) 2007-11-01
JP5001758B2 (ja) 2012-08-15
NZ500253A (en) 2002-09-27
IL132304A0 (en) 2001-03-19
AU2008202516A1 (en) 2008-06-26
AU2005201799A1 (en) 2005-05-26
NO995044L (no) 1999-12-15
AU9523401A (en) 2002-01-24
CA2285746C (en) 2010-09-28
TR199902512T2 (xx) 2000-06-21
EP0975754A1 (en) 2000-02-02
SI0975754T1 (sl) 2007-10-31
BG65242B1 (bg) 2007-09-28
CZ302262B6 (cs) 2011-01-19
SK141999A3 (en) 2000-05-16
BR9808545A (pt) 2000-05-23
HU230547B1 (hu) 2016-11-28
EE9900611A (et) 2000-08-15
DE69837845T2 (de) 2008-01-31
SK288559B6 (sk) 2018-05-02
DK0975754T3 (da) 2007-10-01
US20060246064A1 (en) 2006-11-02
EP0975754B2 (en) 2016-01-06
RO128635A2 (ro) 2013-07-30
DK0975754T4 (en) 2016-03-21
ATE363533T1 (de) 2007-06-15
EA199900939A1 (ru) 2000-08-28
AU779461C (en) 2005-10-13

Similar Documents

Publication Publication Date Title
AU779461C (en) Osteoprotegerin binding proteins and receptors
Kasugai et al. Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter
HU9600692D0 (en) Human metabotropic glutamate receptor subtypes (hmr4, hmr6, hmr7) and related dna compounds
EP2325316B8 (en) Novel hemopoietin receptor protein, NR10
WO1995030003A3 (en) Morphogenic protein-specific cell surface receptors and uses therefor
BR9814335A (pt) Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
EA199700143A1 (ru) Способ и композиция ждя липидизации гидрофильных молекул
EP0679093A1 (en) METHOD FOR PROVIDING AGENTS TO TARGET CELLS.
ES2009590A6 (es) Metodo de preparacion de proteina de cadena pesada del factor tisular humano.
WO1995009872B1 (en) Dna encoding prostaglandin receptor ip
DE69738370D1 (de) Modulatoren des tnf-rezeptor-assoziierten faktors, deren herstellung und verwendungen
EP0861896A3 (de) Zellvolumenregulierte humane Kinase h-sgk
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
WO1997007135A3 (en) Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
BR0013043A (pt) Proteìna isolada, anticorpo isolado, composição, método de regulação de reação imunológica em animais, método de tratamento de câncer em animais, molécula de ácido nucleico isolado, molécula de ácido nucleico recombinante, célula recombinante e vìrus recombinante
EP0369816A3 (en) Monoclonal antibodies specific for human polymorphic epithelial mucin
CA2312274A1 (en) Isolated dna encoding human h3 histamine receptor
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
GEP20002244B (en) Osteoprotegerin
MX9701267A (es) Receptor de glutamato.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180414